Lev S. Butaev

Lev S. Butaev

Auto-generated profile, based on publicly available information

Lev S. Butaev

Moscow Municipal Center for Hematology, SP Botkin City Clinical Hospital, 5 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
OAOlga Aleshina
Olga Aleshina
KZKristina Zakurdaeva
Kristina Zakurdaeva
AVAnastasia N. Vasileva
Anastasia N. Vasileva
SDSergey K. Dubov
Sergey K. Dubov
VDVitaly S. Dubov
Vitaly S. Dubov
EPElena N. Parovichnikova
Elena N. Parovichnikova

15 July 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VVVladimir I. Vorobyev
Vladimir I. Vorobyev
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
LFLiudmila Fedorova
Liudmila Fedorova
NMNatalia B. Mikhailova
Natalia B. Mikhailova
RIRidvan K. Ilyasov
Ridvan K. Ilyasov
КПКалейкина Лилия Павловна
Калейкина Лилия Павловна
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patients with relapsed or refractory (R/R) MCL. Aim. To assess efficacy and toxicity of ibrutinib monotherapy in patients with R/R MCL in routine practice outside of clinical trials. Materials and methods. The study enrolled patients with confirmed R/R MCL who had received at least one line of previous chemotherapy. ECOG 24, cytopenia, infectious complications, hemorrhagic syndrome were not exclusion criteria. Patients received daily oral ibrutinib 560 mg until progression or unacceptable toxicity. Results. From May 2015 to September 2020 ibrutinib therapy was started in 106 patients with R/R MCL in 16 regions of Russia. The median age was 66 years; ECOG2 18%, blastoid variant (or Ki6740% or WBC50109/l) 43%. The median number of previous treatment lines was 2 (111). The ORR was 78.4% (CRR 27.4%). The median PFS was 13.6 months and OS 23.2 months. In the blastoid group the median PFS was 4.4 months vs 36.5 months in the alternative group (p0.001), the median OS 9.0 vs 41.0 (p=0.001). The median OS of patients after progression on ibrutinib was 3.2 months. The common complications are hemorrhages (63%), diarrhea (62%), myalgia and muscle cramps (60%), infections (31%), skin and nail toxicity 15%, arrhythmia 8%. None of recipients had to completely discontinue ibrutinib therapy due to complications. Conclusion. Ibrutinib is effective and well tolerated in routine practice of R/R MCL treatment and our results are consistent with international clinical trials. The favorable toxicity profile and the high response rate made it possible to prescribe ibrutinib in severe somatic status, cytopenia, and even in the presence of infectious complications.

1 April 2026 in Clinical oncohematology
Verified
Journal Article
Open access
LFLiudmila Fedorova
Liudmila Fedorova
NMN. B. Mikhailova
N. B. Mikhailova
KLKirill V. Lepik
Kirill V. Lepik
ACA. M. Chekalov
A. M. Chekalov
OSO. G. Smykova
O. G. Smykova
AKAlexander Kulagin
Alexander Kulagin
BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
LBLev S. Butaev
Lev S. Butaev
MSM. A. Sannikova
M. A. Sannikova
YKYa. V. Krylova
Ya. V. Krylova
SVS. V. Vlasova
S. V. Vlasova
FBF. E. Babaeva
F. E. Babaeva
VPVadim V. Ptushkin
Vadim V. Ptushkin
Aim. To evaluate the efficacy and safety of mosunetuzumab monotherapy in real clinical practice. Materials and methods. The evaluation of the study results included clinical data from 17 patients with follicular lymphoma (7 women and 10 men) who received mosunetuzumab monotherapy in 4 centers of the Russian Federation from November 9, 2021 to April 3, 2025: Botkin Hospital (11 patients), Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation (4 patients), Yaroslavl Regional Clinical Hospital (1 patient), and the National Medical Research Center for Hematology (1 patient). In the evaluated sample, the majority of patients, 15 (88.2 %) people, had a histological variant of the disease: cytological type follicular lymphoma 1–3A. The median age was 43 (22–61) years. All 17 patients had advanced disease stage (III–IV) according to the Ann Arbor classification at the time of diagnosis. The primary endpoint was the frequency of complete response (percentage of patients) over the entire treatment period. Efficacy criteria: overall response rate (complete and partial response) over the entire treatment period, overall and progression-free survival, as well as safety assessment. Results. The overall response rate was 76.4 % (n = 13). Complete response was achieved in 10 (58.8 %) patients. Disease stabilization was observed in 3 (17.6 %) patients, and disease progression was detected in 1 (5.8 %) patient. The median number of mosunetuzumab courses was 6 (2–17). With a median follow-up of 31 (1–43) months in the patient group, the median progression-free survival and overall survival were not achieved. At 42 months, progression-free and overall survival were 67 and 81 %, respectively. Most of the adverse events were mild (I–II). The most common adverse events were hematological complications: anemia, neutropenia, and thrombocytopenia. Grade III–IV adverse events also included anemia (n = 2 (11.7 %)), thrombocytopenia (n = 3 (17.6 %)), and neutropenia (n = 8 (47.0)). Transfusion of blood components was required in 3 (17.6 %) patients. In 1 (5.8 %) case, an episode of febrile neutropenia was noted. Conclusion. The use of mosunetuzumab in real clinical practice has demonstrated high efficacy and a manageable toxicity profile comparable to published data. The results obtained allow us to consider the use of mosunetuzumab as an alternative treatment regimen for patients with relapsed / refractory follicular lymphoma.

6 July 2026 in Blood Immunology & Cellular Therapy
Verified
Journal Article
Open access
LFLiudmila Fedorova
Liudmila Fedorova
NMNatalia Mikhailova
Natalia Mikhailova
KLKirill V. Lepik
Kirill V. Lepik
VMVladislav Markelov
Vladislav Markelov
ACAndrey Chekalov
Andrey Chekalov
AKAlexander Kulagin
Alexander Kulagin